Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, et al.
NEJM Evidence (2022) Vol. 1, Iss. 7
Closed Access | Times Cited: 532

Showing 1-25 of 532 citing articles:

Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
Lachelle D. Weeks, Abhishek Niroula, Donna Neuberg, et al.
NEJM Evidence (2023) Vol. 2, Iss. 5
Open Access | Times Cited: 163
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 143
Recent advances in targeted therapies in acute myeloid leukemia
Rahul S. Bhansali, Keith W. Pratz, Catherine Lai
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 123
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, et al.
The Lancet (2023) Vol. 402, Iss. 10399, pp. 373-385
Closed Access | Times Cited: 103
Germ lineDDX41mutations define a unique subtype of myeloid neoplasms
Hideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Blood (2022) Vol. 141, Iss. 5, pp. 534-549
Open Access | Times Cited: 96
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Guillermo Garcia‐Manero
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1307-1325
Open Access | Times Cited: 94
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2827-2842
Open Access | Times Cited: 66
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
Saverio D’Amico, Daniele Dall’Olio, Claudia Sala, et al.
JCO Clinical Cancer Informatics (2023), Iss. 7
Open Access | Times Cited: 47
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates
Valeria Santini, Maximilian Stahl, David A. Sallman
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 16
Non canonical c-CBL mutations define a specific phenotype of myeloid neoplasia
Luca Guarnera, Carmelo Gurnari, Carlos Bravo‐Pérez, et al.
Leukemia (2025)
Open Access | Times Cited: 2
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages
Simone Feurstein, Amy M. Trottier, Noel Estrada‐Merly, et al.
Blood (2022) Vol. 140, Iss. 24, pp. 2533-2548
Open Access | Times Cited: 69
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
Hui Yang, Guillermo Garcia‐Manero, Koji Sasaki, et al.
Leukemia (2022) Vol. 36, Iss. 9, pp. 2306-2316
Open Access | Times Cited: 66
VEXAS Syndrome: A Novelty in MDS Landscape
Marie Templé, Olivier Kosmider
Diagnostics (2022) Vol. 12, Iss. 7, pp. 1590-1590
Open Access | Times Cited: 44
DDX41-associated susceptibility to myeloid neoplasms
Hideki Makishima, Teresa V. Bowman, Lucy A. Godley
Blood (2022) Vol. 141, Iss. 13, pp. 1544-1552
Open Access | Times Cited: 40
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
Jurjen Versluis, Wael Saber, Harrison Tsai, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 28, pp. 4497-4510
Open Access | Times Cited: 32
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e38-e50
Closed Access | Times Cited: 31
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e15-e26
Closed Access | Times Cited: 27
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Nikolaus Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia (2023) Vol. 37, Iss. 11, pp. 2187-2196
Open Access | Times Cited: 26
m6A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis
Maciej Cieśla, Phuong Cao Thi Ngoc, Sowndarya Muthukumar, et al.
Molecular Cell (2023) Vol. 83, Iss. 7, pp. 1165-1179.e11
Open Access | Times Cited: 24
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1
Jonathan F. Thomas, Marco Igor Valencia‐Sánchez, Simone Tamburri, et al.
Science Advances (2023) Vol. 9, Iss. 32
Open Access | Times Cited: 24
Diagnosis and classification of myelodysplastic syndromes
Robert P. Hasserjian, Ulrich Germing, Luca Malcovati
Blood (2023) Vol. 142, Iss. 26, pp. 2247-2257
Closed Access | Times Cited: 24
Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes
Tariq Kewan, Waled Bahaj, Arda Durmaz, et al.
Blood (2023) Vol. 141, Iss. 14, pp. 1768-1772
Open Access | Times Cited: 23
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
Maria Sirenko, Elsa Bernard, Maria Creignou, et al.
Blood (2024) Vol. 144, Iss. 11, pp. 1221-1229
Closed Access | Times Cited: 15
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, et al.
Blood Advances (2024) Vol. 8, Iss. 15, pp. 4209-4220
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top